Logo image of COCP

COCRYSTAL PHARMA INC (COCP) Stock Fundamental Analysis

NASDAQ:COCP - Nasdaq - US19188J4094 - Common Stock - Currency: USD

1.701  -0.06 (-3.35%)

Fundamental Rating

2

COCP gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 192 industry peers in the Pharmaceuticals industry. The financial health of COCP is average, but there are quite some concerns on its profitability. COCP is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

COCP had negative earnings in the past year.
In the past year COCP has reported a negative cash flow from operations.
In the past 5 years COCP always reported negative net income.
COCP had a negative operating cash flow in each of the past 5 years.
COCP Yearly Net Income VS EBIT VS OCF VS FCFCOCP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20M -40M -60M -80M -100M

1.2 Ratios

COCP has a worse Return On Assets (-115.21%) than 80.21% of its industry peers.
COCP has a Return On Equity of -147.23%. This is in the lower half of the industry: COCP underperforms 66.15% of its industry peers.
Industry RankSector Rank
ROA -115.21%
ROE -147.23%
ROIC N/A
ROA(3y)-56.87%
ROA(5y)-71.48%
ROE(3y)-61.52%
ROE(5y)-78.07%
ROIC(3y)N/A
ROIC(5y)N/A
COCP Yearly ROA, ROE, ROICCOCP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -50 -100 -150

1.3 Margins

COCP does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
COCP Yearly Profit, Operating, Gross MarginsCOCP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20K -40K -60K

More info and screens

6

2. Health

2.1 Basic Checks

COCP has more shares outstanding than it did 1 year ago.
The number of shares outstanding for COCP has been increased compared to 5 years ago.
COCP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
COCP Yearly Shares OutstandingCOCP Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M
COCP Yearly Total Debt VS Total AssetsCOCP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M

2.2 Solvency

COCP has an Altman-Z score of -28.75. This is a bad value and indicates that COCP is not financially healthy and even has some risk of bankruptcy.
COCP's Altman-Z score of -28.75 is on the low side compared to the rest of the industry. COCP is outperformed by 88.02% of its industry peers.
There is no outstanding debt for COCP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -28.75
ROIC/WACCN/A
WACCN/A
COCP Yearly LT Debt VS Equity VS FCFCOCP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M 100M 150M

2.3 Liquidity

COCP has a Current Ratio of 7.32. This indicates that COCP is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 7.32, COCP is doing good in the industry, outperforming 76.56% of the companies in the same industry.
A Quick Ratio of 7.32 indicates that COCP has no problem at all paying its short term obligations.
With a decent Quick ratio value of 7.32, COCP is doing good in the industry, outperforming 77.60% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 7.32
Quick Ratio 7.32
COCP Yearly Current Assets VS Current LiabilitesCOCP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M

More info and screens

0

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 7.96% over the past year.
EPS 1Y (TTM)7.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-19.51%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, COCP will show a very negative growth in Earnings Per Share. The EPS will decrease by -11.47% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-3.61%
EPS Next 2Y-7.68%
EPS Next 3Y-11.47%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
COCP Yearly Revenue VS EstimatesCOCP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2M 4M 6M
COCP Yearly EPS VS EstimatesCOCP Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

COCP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year COCP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
COCP Price Earnings VS Forward Price EarningsCOCP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
COCP Per share dataCOCP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

COCP's earnings are expected to decrease with -11.47% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-7.68%
EPS Next 3Y-11.47%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for COCP!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

COCRYSTAL PHARMA INC

NASDAQ:COCP (3/7/2025, 8:15:43 PM)

1.701

-0.06 (-3.35%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-13 2024-11-13/bmo
Earnings (Next)03-26 2025-03-26/amc
Inst Owners6.99%
Inst Owner Change-1.09%
Ins Owners12.02%
Ins Owner Change0.57%
Market Cap17.30M
Analysts82.5
Price Target8.5 (399.71%)
Short Float %0.21%
Short Ratio0.27
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)3.36%
Min EPS beat(2)-9.01%
Max EPS beat(2)15.72%
EPS beat(4)3
Avg EPS beat(4)15.9%
Min EPS beat(4)-9.01%
Max EPS beat(4)29.19%
EPS beat(8)7
Avg EPS beat(8)18.91%
EPS beat(12)8
Avg EPS beat(12)-30.62%
EPS beat(16)11
Avg EPS beat(16)-19.6%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)4.17%
EPS NQ rev (1m)0%
EPS NQ rev (3m)5.36%
EPS NY rev (1m)0%
EPS NY rev (3m)1.53%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.36
P/tB 1.36
EV/EBITDA N/A
EPS(TTM)-1.85
EYN/A
EPS(NY)-2.2
Fwd EYN/A
FCF(TTM)-1.64
FCFYN/A
OCF(TTM)-1.64
OCFYN/A
SpS0
BVpS1.25
TBVpS1.25
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -115.21%
ROE -147.23%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-56.87%
ROA(5y)-71.48%
ROE(3y)-61.52%
ROE(5y)-78.07%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 48.18%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.32
Quick Ratio 7.32
Altman-Z -28.75
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)41.86%
Cap/Depr(5y)85.12%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)7.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-19.51%
EPS Next Y-3.61%
EPS Next 2Y-7.68%
EPS Next 3Y-11.47%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-1.62%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-6.17%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y14.4%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y14.43%
OCF growth 3YN/A
OCF growth 5YN/A